Oncolytics Biotech   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Calgary Canada (1998)

Organization Overview

First Clinical Trial
2006
NCT00528684
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Oncolytics Biotech

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 3)

Carcinoma, Transitional Cell (Phase 1)

Colorectal Neoplasms (Phase 2)

Fibrosarcoma (Phase 2)

Glioma (Phase 1)

Histiocytoma (Phase 2)

Histiocytoma, Benign Fibrous (Phase 2)

Histiocytoma, Malignant Fibrous (Phase 2)

Leiomyosarcoma (Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Osteosarcoma (Phase 2)

Prostatic Neoplasms (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Sarcoma, Synovial (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial APIs: 28